Results 171 to 180 of about 3,633,295 (206)

Neurobiological mechanisms of 40‐Hz stimulation in Alzheimer's disease: evidence, heterogeneity, and constraints

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract Early disruption of gamma oscillations is increasingly recognized as a contributor to neurodegeneration and cognitive decline in Alzheimer's disease (AD), positioning 40‐Hz stimulation as a promising neuromodulatory strategy. However, its neurophysiological and cognitive effects remain highly variable across studies, underscoring the need for ...
Lin Qi, Weiye Wang, Reema Abdullah, Yilei Zhao, Zhibin Wang, Yi Tang, Benyan Luo, Guoping Peng   +7 more
wiley   +1 more source

Increased Amyloidogenic Neuronal Injury in HIV‐1–infected APP‐KI Alzheimer's disease mice

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION A higher incidence of dementia, including Alzheimer's‐like pathology, is observed in aged people living with human immunodeficiency virus‐1 (HIV‐1). However, mechanisms linking HIV‐1 to Alzheimer's disease (AD) pathology remain unclear, due to the lack of animal models that allow for concurrent studies of HIV‐1 and AD.
Shaurav Bhattarai, Emma G. Foster, Rana Kadry, Yaman Lu, Mohit Kumar, Syed Qasim, Amrita Mitra, Harsh Pathak, Larisa Y. Poluektova, Santhi Gorantla, R. Lee Mosley, Pravin Yeapuri, Howard E. Gendelman   +12 more
wiley   +1 more source

Performance of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) biomarkers in predicting CT scan results and neurological outcomes in children with traumatic brain injury (BRAINI-2 paediatric study): protocol of a European prospective multicentre study. [PDF]

BMJ Open
Lorton F, Lagares A, de la Cruz J, Méjan O, Pavlov V, Sapin V, Poca MA, Lehner M, Biberthaler P, Chauviré-Drouard A, Gras-Le-Guen C, Scherdel P, BRAINI–2 paediatric Collaborative group, Collaborators.   +13 more
europepmc   +1 more source

Female vulnerability to microvascular transport dysfunction emerges early across the Alzheimer's disease continuum

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION We tested whether quantitative transport mapping (QTM)‐derived perfusion velocity would detect earlier and more sex‐specific microvascular alterations than cerebral blood flow (CBF) across the Alzheimer's disease (AD) continuum.
Manxi Xu, Yian Gao, Peiling Ou, Haoyu Yang, Jia Wang, Wulong Liu, Ni Shu, Yu Sun, Liping Fu, Lidia Glodzik, Tracy A Butler, Gloria C Chaing, Yi Li, Yi Wang, Liangdong Zhou, Guolin Ma   +15 more
wiley   +1 more source

Aberrant phase separation from a rare ABI3 mutation drives microglial dysfunction and Alzheimer's risk

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION Although the ABI3 S209F variant is a recognized genetic risk for Alzheimer's disease (AD), its pathogenic mechanism remains elusive. METHODS Using AD mouse models (amyloid precursor protein/presenilin 1 [APP/PS1] transgenic mice, 5×familial Alzheimer's disease (5×FAD) transgenic mice) with microglia‐specific knockdown of Abelson ...
Shengnan Li, Jiongtong Lu, Kaixing Zeng, Xingyu Lu, Jiahao Zhang, Sifan Feng, Chunmei Liang, Yujie Cai, Shi Yao, Qing Huang, Guocong Liang, Rui Chen, Li Li, Fubin Ma, Jiawei Xing, Chaoyue Ouyang, Lv Luo, Jiaying Wang, You Li, Shengbo He, Yuanyuan Zhao, Yan Wang, Lili Cui   +22 more
wiley   +1 more source

Alterations of gut microbiota in Down syndrome and their association with Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION Adults with Down syndrome (DS) have a higher risk of Alzheimer's disease (AD). As gut microbiota (GM) alterations have been reported in AD, we investigated their association with cognitive decline and plasma AD biomarkers in DS.
Camilla Pellegrini, Francesco Ravaioli, Sara De Fanti, Alessia Siliquini, Claudia Sala, Magali Rochat, Virginia Pollarini, Barbara Polischi, Alberto Pasti, Margherita Grasso, Maria Rambaldi, Francesco Cardoni, Nicola Grotteschi, Filippo Caraci, Pietro Cortelli, Federica Provini, Raffaele Lodi, Luca Morandi, Piero Parchi, Gian Luca Pirazzoli, Luisa Sambati, Caterina Tonon, Maria Giulia Bacalini   +22 more
wiley   +1 more source

Operationalizing Alzheimer's disease trials in the era of targeted therapies

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract The therapeutic landscape of Alzheimer's disease (AD) is rapidly evolving with the clinical adoption of anti‐amyloid monoclonal antibodies (mAbs) despite an incomplete understanding of disease mechanisms, progression, and heterogeneity. Designing both observational longitudinal cohorts and clinical trials with novel mAbs in mind is imperative.
Jagan A. Pillai, Suvarna Alladi, Brian S. Appleby, Jared Robert Brosch, Kristian Steen Frederiksen, Douglas Galasko, Oscar L. Lopez, James B. Leverenz, Andrew J. Saykin, Jonathan M. Schott, Sudha Seshadri, Babak Tousi, David A. Wolk   +12 more
wiley   +1 more source